AIC
AKBA icon

Archer Investment Corporation’s Akebia Therapeutics AKBA Stock Holding History

Archer Investment Corporation’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,800
Closed -$24.6K – 1045
2023
Q4 		$24.6K Buy
+19,800
New +$20.2K 0.01% 496
2020
Q2 		– Sell
-300
Closed -$2K – 650
2020
Q1 		$2K Hold
300
– – ﹤0.01% 521
2019
Q4 		$2K Hold
300
– – ﹤0.01% 545
2019
Q3 		$1K Hold
300
– – ﹤0.01% 465
2019
Q2 		$1K Hold
300
– – ﹤0.01% 455
2019
Q1 		$2K Hold
300
– – ﹤0.01% 433
2018
Q4 		$2K Buy
+300
New +$2.35K ﹤0.01% 399

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Archer Investment Corporation's AKBA Position: Q1 2024 in Review

Archer Investment Corporation sold out of Akebia Therapeutics (AKBA) in Q1 2024, closing a stake of 19,800 shares — an estimated $24.6K sold.

Archer Investment Corporation first reported a position in AKBA in Q4 2018 and held it in 7 quarters. The position peaked at $24.6K in Q4 2023. 114 funds tracked by Wall St. Rank hold AKBA as of Q1 2024.

  • Archer Investment Corporation reported no remaining Akebia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Archer Investment Corporation sold 19,800 Akebia Therapeutics shares in Q1 2024, an estimated $24.6K.
  • Archer Investment Corporation first reported a position in Akebia Therapeutics in Q4 2018 and held it in 7 quarters.
  • Archer Investment Corporation's Akebia Therapeutics position peaked at $24.6K in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2024.

Based on Archer Investment Corporation's 13F filing for Q1 2024, filed 9 May 2024.